The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

Published Date: 22 Sep 2023

The US Food and Drug Administration (FDA) has approved JAK inhibitor momelotinib (Ojjaara) as the initial treatment specifically for.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

2.

AI tool identifies women at high risk of interval breast cancer

3.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Kate Middleton Reaches Cancer Treatment Milestone


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot